- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT05885022
Feasibility Clinical Evaluation of the Calibreye System
August 17, 2023 updated by: Myra Vision Inc.
To evaluate the safety and feasibility of the Calibreye System in patients with open angle glaucoma.
Study Overview
Detailed Description
This is a prospective, nonrandomized, open-label feasibility clinical trial, to evaluate the surgical procedure, safety and effectiveness of the Calibreye System in reducing intraocular pressure in subjects with open angle glaucoma.
Study Type
Interventional
Enrollment (Estimated)
30
Phase
- Not Applicable
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Contact
- Name: Robert Chang
- Phone Number: 14085602500
- Email: info@myravision.com
Study Contact Backup
- Name: Barbara Niksch
- Phone Number: 19495336101
Study Locations
-
-
-
Chennai, India, 600018
- Recruiting
- Dr. Agarwal's Eye Hospital Ltd.
-
Contact:
- Priyanka Shankar
- Phone Number: (91) 97698 37574
- Email: priyanka.s@dragarwal.com
-
Principal Investigator:
- Ashvin Agarwal, MD
-
-
-
-
-
Puebla, Mexico, 72540
- Recruiting
- Oftalmología Láser de Puebla S.C.
-
Contact:
- Aimee Hernandez
- Phone Number: (22) 2257-0970
- Email: aimeehdz20@gmail.com
-
Principal Investigator:
- Gabriel Salomón Lazcano Gómez, MD
-
-
-
-
-
Panama City, Panama
- Recruiting
- Panama Eye Center
-
Contact:
- Idabel Orillac
- Phone Number: +507 269 7475
- Email: idabelo28@gmail.com
-
Principal Investigator:
- Ernesto Calvo, MD
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
- Adult
- Older Adult
Accepts Healthy Volunteers
Yes
Description
Inclusion Criteria:
- Open angle, pseudoexfoliative or pigmentary glaucoma
- IOP at preoperative visit of ≥ 18mmHg and ≤ 45mmHg
- Visual field mean deviation score of -3dB or worse
- Area of healthy, free and mobile conjunctiva in the target quadrant
- Shaffer angle grade ≥ 3 in the target quadrant
Exclusion Criteria:
- Angle closure glaucoma
- Congenital, neovascular or other secondary glaucomas
- Previous intraocular surgery (with the exception of laser trabeculoplasty or uncomplicated phacoemulsification with IOL occurring > 3 months prior to the preoperative visit)
- Previous glaucoma shunt/valve in the target quadrant
- Clinically significant inflammation or infection in the study eye within 30 days prior to the preoperative visit
- History of corneal surgery, corneal opacities or corneal disease
- Active diabetic retinopathy
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: N/A
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Investigational Device Arm
Subjects will receive a Calibreye glaucoma device (permanent implant)
|
Implantation of a glaucoma device to reduce intraocular pressure
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Intraocular Pressure
Time Frame: 12 Months
|
Percent change in IOP from baseline to the 12-month visit
|
12 Months
|
Adverse Events
Time Frame: 12 Months
|
Number and percentage of subjects having any adverse event
|
12 Months
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Glaucoma Medication Usage
Time Frame: 12 Months
|
Change in number of medications used compared to baseline
|
12 Months
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Investigators
- Study Chair: Keith Barton, MD, Moorfields Eye Hospital NHS Foundation Trust
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start (Actual)
May 31, 2023
Primary Completion (Estimated)
December 1, 2024
Study Completion (Estimated)
April 1, 2025
Study Registration Dates
First Submitted
May 22, 2023
First Submitted That Met QC Criteria
May 22, 2023
First Posted (Actual)
June 1, 2023
Study Record Updates
Last Update Posted (Actual)
August 21, 2023
Last Update Submitted That Met QC Criteria
August 17, 2023
Last Verified
August 1, 2023
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- CFP-101, CFP-102, CFP-103
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
NO
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
No
Studies a U.S. FDA-regulated device product
Yes
product manufactured in and exported from the U.S.
Yes
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Glaucoma, Open-Angle
-
AllerganRecruiting18 Month Prospective Efficacy and Safety Study of Bimatoprost Intracameral Implant (DURYSTA) (ARGOS)Ocular Hypertension | Open-angle GlaucomaUnited States
-
Aerie PharmaceuticalsCompletedOcular Hypertension | Open-angle Glaucoma
-
West Virginia UniversityUniversity of Pittsburgh; University of MichiganWithdrawnOpen-angle Glaucoma
-
Glaukos CorporationUnknownOpen-Angle GlaucomaSpain, Germany, Austria, Turkey
-
Alcon ResearchWithdrawnOpen-Angle Glaucoma
-
Asociación para Evitar la Ceguera en MéxicoUnknown
-
Pharmaceutical Research NetworkCompleted
-
National Eye Institute (NEI)CompletedOpen-Angle Glaucoma
Clinical Trials on Calibreye System
-
ResMedCompleted
-
Federal University of São PauloCompletedAdverse Reaction to Systemic AgentsBrazil
-
KineticureCompletedOsteoarthritis | Knee PainUnited States
-
Smith & Nephew, Inc.CompletedDiabetic Foot Ulcers | Venous Leg UlcersUnited States, Canada
-
Molnlycke Health Care ABCompletedEvaluation of Negative Pressure Wound Therapy in the Treatment of DFUs Incl. Post Amputation Wounds.Diabetes | Foot UlcersUnited Kingdom
-
Zahedan University of Medical SciencesUnknownPain, Postoperative Pain Pathologic Processes Postoperative Complications Signs and Symptoms
-
University of British ColumbiaNot yet recruitingPersistent Developmental Stutter | Childhood-Onset Fluency Disorder (Stuttering)
-
National Institute of Neurological Disorders and...Recruiting
-
Buckinghamshire Healthcare NHS TrustUnknown